With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy. Bispecific antibodies can target two different antigens at the same time, such as simultaneously binding tumor cell receptors and recruiting cytotoxic immune cells. Structural diversity has been fast-growing in the bispecific antibody field, creating a plethora of novel bispecific antibody scaffolds, which provide great functional variety. Two common formats of bispecific antibodies on the market are the single-chain variable fragment (scFv)-based (no Fc fragment) antibody and the full-length IgG-like asymmetric antibody. Unlike the conventional monoclonal antibodies, great production challenges with respect to the quantity, quality, and stability of bispecific antibodies have hampered their wider clinical application and acceptance. In this review, we focus on these two major bispecific types and describe recent advances in the design, production, and quality of these molecules, which will enable this important class of biologics to reach their therapeutic potential.

Qiong Wang

Yiqun Chen

Jaeyoung Park

Xiao Liu

Yifeng Hu

Tiexin Wang

Kevin McFarland

Michael J. Betenbaugh

Antibodies

Antibodies (ISSN 2073-4468), an international, peer-reviewed open access journal which provides an advanced forum for studies related to antibodies and antigens. It publishes reviews, research articles, communications and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. Full experimental and/or methodical details must be provided. Electronic files or software regarding the full details of the calculation and experimental procedure - if unable to be published in a normal way - can be deposited as supplementary material.  This journal covers all topics related to antibodies and antigens, topics of interest include (but are not limited to):    antibody-producing cells (including B cells),  antibody structure and function,  antibody-antigen interactions,  Fc receptors,  antibody manufacturing  antibody engineering,  antibody therapy,  immunoassays,  antibody diagnosis,  tissue antigens,  exogenous antigens,  endogenous antigens,  autoantigens,  monoclonal antibodies,  natural antibodies,  humoral immune responses,  immunoregulatory molecules.

Antibodies is an international, peer-reviewed open access journal that provides an advanced forum for studies related to antibodies and antigens. It publishes reviews, research articles, communications, and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There are no restrictions on the length of the papers, and full experimental and/or methodological details must be provided. Electronic files or software regarding the full details of the calculations and experimental procedures—if unable to be published in a conventional manner—can be deposited as supplementary material. This journal covers all topics related to antibodies and antigens. Topics of interest include (but are not limited to): antibody-producing cells (including B cells), antibody structure and function, antibody-antigen interactions, Fc receptors, antibody manufacturing, antibody engineering, antibody therapy, immunoassays, antibody diagnosis, tissue antigens, exogenous antigens, endogenous antigens, autoantigens, monoclonal antibodies, natural antibodies, humoral immune responses, and immunoregulatory molecules.

《Antibodies》是一本国际性的、经过同行评审的开放获取期刊，专注于抗体和抗原相关的研究。期刊发表综述、研究文章、通讯和简短的笔记，旨在鼓励科学家尽可能详细地发布他们的实验和理论结果。对论文的长度没有限制，必须提供完整的实验和/或方法细节。如果无法以常规方式发表的计算和实验过程的电子文件或软件，可以作为补充材料存放。该期刊涵盖与抗体和抗原相关的所有主题，感兴趣的主题包括（但不限于）：抗体产生细胞（包括B细胞）、抗体的结构与功能、抗体-抗原相互作用、Fc受体、抗体制造、抗体工程、抗体疗法、免疫测定、抗体诊断、组织抗原、外源性抗原、内源性抗原、自身抗原、单克隆抗体、天然抗体、体液免疫反应和免疫调节分子。

Design and Production of Bispecific Antibodies

Two common formats of bispecific antibodies on the market are the single-chain variable fragment (scFv)-based (no Fc fragment) antibody and the full-length IgG-like asymmetric antibody, which are focused on in this review.

Design and Production of Bispecific Antibodies

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
IMMUNOLOGY	3